Clinical trial
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's…
NCT00285428 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00285428 |
|---|---|
| Title | Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma |
| Official title | A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non-Hodgkin's Lymphoma |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | hA20-humanized anti-CD20 antibody |
| Enrollment | 82 |
| Start date | Sep 1, 2004 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Feb 2, 2006 |
| Last update posted | Aug 17, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: